Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 22, 2022 08:00 ET | Source: Acrivon Therapeutics

Acrivon Therapeutics Receives FDA Clearance for Innovative Phase 2 Trial to Treat Ovarian, Endometrial and Urothelial Cancer Patients Based on Predicted Sensitivity to ACR-368

--Pioneering trial will be using a first-of-its-kind OncoSignature® companion diagnostic to identify and treat patients that are predicted most likely to benefit from treatment— ...
April 20, 2022 08:00 ET | Source: Acrivon Therapeutics

Acrivon Therapeutics Announces the Appointments of Rasmus Holm-Jorgensen as Chief Financial Officer and Other Senior Executives

WATERTOWN, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc., a clinical-stage oncology therapeutics company with proprietary technologies driving a new era of precision-based...
March 16, 2022 08:00 ET | Source: Acrivon Therapeutics

Acrivon Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference

WATERTOWN, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc., a clinical-stage oncology therapeutics company with proprietary technologies driving a new era of precision-based...
December 08, 2021 08:00 ET | Source: Acrivon Therapeutics

Acrivon Therapeutics Announces its Scientific Advisory Board with Renowned Oncology Thought Leaders

WATERTOWN, Mass., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc., a clinical-stage oncology therapeutics company with proprietary, proteomics-based technologies driving a new era of...
November 29, 2021 08:00 ET | Source: Acrivon Therapeutics

Acrivon Therapeutics to Present at the Evercore ISI HealthCONx Conference

WATERTOWN, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc., a clinical-stage oncology therapeutics company with proprietary technologies driving a new era of precision-based...
November 11, 2021 08:00 ET | Source: Acrivon Therapeutics

Acrivon Therapeutics Closes Oversubscribed $100 Million Series B Financing to Advance its Innovative Precision Proteomics Platform and Clinical Oncology Pipeline

Proceeds to support the clinical development of advanced Phase 2 lead asset ACR-368, a potent DNA Damage Response (DDR) inhibitor clinically validated in solid cancers, and in-house drug pipeline...
June 29, 2021 08:00 ET | Source: Acrivon Therapeutics

Acrivon Therapeutics Launches to Advance Clinical Oncology Pipeline Leveraging its Groundbreaking Precision Proteomics Platform

Acrivon signs exclusive worldwide license agreement with Eli Lilly and Company to develop and commercialize prexasertib, a clinically advanced, selective inhibitor targeting DNA Damage Response (DDR)...